Patients with nonerosive gastroesophageal reflux disease often have relatively low esophageal acid exposure and respond suboptimally to gastric acid suppression. In these patients, other constituents of gastric contents may induce esophageal symptoms. We have demonstrated that gastric contents can cause heartburn when the gastric pH > 4. (Aliment Pharm Ther 14:129–134, 2000). The aim of this study was to determine relative sensitivities to chenodeoxycholic and ursodeoxycholic acids, and 0.1 N HCl, administered as provocative perfusion tests. Patients with functional heartburn and healthy control subjects were evaluated. Patients underwent a modified Bernstein acid infusion test and esophageal Barostat balloon distention. Time and volume to pain were recorded. Barostat balloon distention was performed using our standard protocol. Stepwise distentions were performed and pain was recorded. Sensitivity to chenodeoxycholic acid (Cheno) and Ursodeoxycholic acid (Urso) were assessed similarly to the Bernstein test using 2 mM concentrations of each, followed immediately by 5 mM if no pain was reported with 2 mM. Volume of bile acid infusion and length of time until pain was induced were assessed and compared to the same endpoints for acid sensitivity. “Total” time and “total” volume to induce pain were calculated for Cheno and Urso. Least-squares means were generated and two-tailed t-tests and regression analyses were performed (P < 0.05 level of significance). Ten functional heartburn patients and six healthy controls were evaluated (3 M, 13 F; age range, 19 to 56 years). Since five of six controls had pain with acid infusion (hypersensitive), all subjects were analyzed as one group. Only three subjects (all controls) had no pain with infusion of 2 mM Cheno and received the follow-up infusion of 5 mM. These same three subjects tolerated the maximum infusion (150 ml and 15 min) of 5 mM Cheno. Nine subjects did not have pain with 2 mM Urso and received the follow-up infusion of 5 mM Urso (five functional heartburn, four controls). Significantly more subjects tolerated the maximum bile acid infusion of 2 mM Urso vs 2 mM Cheno (nine vs three; P < 0.05, Chi-square test). The pain threshold (volume and time) for Urso was significantly higher than that for Cheno and acid (P < 0.05), and the pain threshold for Cheno was significantly higher than that for acid (P < 0.05). Conclusions are as follows: (1) Bile acids differ in their ability to induce pain. (2) Changing bile acid composition by treatment with Urso may change symptom presentation and symptom severity in patients with bile acid-induced esophageal pain.
Similar content being viewed by others
References
Rodriguez SL, Earnest DL, Greenwood-Van Meerveld B, Maton P, Miner PB, Robinson M: Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol 94(3):628–631, 1999
Drossman DA: Rome II: The Functional Gastrointestinal Disorders, 2nd ed. 2000
Rodriguez-Stanley S, Zubaidi S, Ciociola A, Miner P: Are patients with functional heartburn sensitive to both mechanical and chemical stimuli?. Am J Gastroenterol 97(9):A115, 2002
Rodriguez-Stanley S, Ciociola A, Bochenek W, Zubaidi S, Miner PB: Ranitidine 150 mg rapidly increases pain threshold and decreases symptom severity with acid infusion in patients with functional heartburn. Gastroenterology 124(4, Suppl 1):A221, 2003
Schidlbeck NE, Heinrich C, Stellard F, Paumgartner G, Muller-Lissner SA: Healthy controls have as much bile reflux as gastric ulcer patients. Gut 88:1577–1583, 1987
Vaezi MF, Singh S, Richter JE: Role of acid and duodenogastric reflux in esophageal mucosal injury: A review of animal and human studies. Gastroenterology 108:1897–1907, 1995
Champion G, Richter JE, Vaezi MF, Singh S, Alexander R: Duodenogastroesophageal reflux: Relationship to pH and importance in Barrett’s esophagus. Gastroenterology 107:747–754, 1994
Attwood SE, Ball CS, Barlow AP, Jenkinson L, Norris TL, Watson A: Role of intragastric and intraesophageal alkalinization in the genesis of complications in Barrett’s columnar lined lower esophagus. Gut 34:11–15, 1993
Harmon JW, Johnson LF, Maydonvitch CL: Effects of acid and bile salts on the rabbit esophageal mucosa. Dig Dis Sci 26:65–72, 1981
Vaezi MF, Richter JE: Duodenogastro-oesophageal reflux. Baillieres Best Pract Res Clin Gastroenterol 14(5):719–729, 2000
Thiesen J, Peters JH, Stein HJ: Experimental evidence for mutagenic potential of duodenogastric juice on Barrett’s esophagus. World J Surg 27:1018–1020, 2003
Stefaniwsky AB, Speck TJ, Shefer SS: Ursodeoxycholic acid treatment of bile reflux gastritis. Gastro 89:1000–1004, 1985
Im E, Martinez JD: Ursodeoxycholic acid (UDCA). J Nutr 134:483–486, 2004
Bernstein LM, Baker LA: A clinical test for esophagitis. Gastroenterology 34:760–781, 1958
Thaysen EH, Pedersen I: Idiopathic bile acid catharsis. Gut 17(12):965–970, 1976
Gelbman CM, Schteingart CD, Thompson SM, Hofman AF, Barrett KE: Mast Cells and histamine contribute to bile acid-stimulated secretion in the mouse colon. J Clin Invest 95:2831–2839, 1995
Rodriguez-Stanley S, Zubaidi S, Miner PB. Esophageal sensitivity to barostat balloon distention and Bernstein acid infusion: which test is best?. Am J Gastroenterology 96(9):A:103, 2001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Siddiqui, A., Rodriguez-Stanley, S., Zubaidi, S. et al. Esophageal Visceral Sensitivity to Bile Salts in Patients with Functional Heartburn and in Healthy Control Subjects. Dig Dis Sci 50, 81–85 (2005). https://doi.org/10.1007/s10620-005-1282-0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10620-005-1282-0